China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Related Insights
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Whitepaper
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Related Insights
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Whitepaper
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026